5 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen

4. Repligen Corporation (NASDAQ:RGEN)

Point72 Asset Management: $164,893,957

On May 7, Barclays raised Repligen Corporation (NASDAQ:RGEN)’s price goal to $160 from $145. It maintained an “Overweight rating” on the stock.

On April 17, 2026, Repligen Corporation (NASDAQ:RGEN) officially opened its third Training & Innovation Center at its OPUS Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands. The site adds to the company’s existing centers in Waltham, Massachusetts, and Tokyo, Japan.

According to CEO Olivier Loeillot, the Breda center provides workshops for technical teams and customers, while also showcasing the company’s vast and diversified bioprocessing portfolio. The facility highlights Repligen Corporation’s entire bioprocessing technology portfolio. It included upstream intensification tools like XCell ATF and KrosFlo TFDF devices, along with downstream offerings like OPUS chromatography columns, Spectrum hollow fiber filters, capital equipment systems, and fluid management products.

Loeillot noted that the inauguration, together with previous investments in the Asia Pacific and the United States, reflects Repligen Corporation (NASDAQ:RGEN)’s commitment to serving customers globally.

Repligen Corporation (NASDAQ:RGEN) is a global life sciences firm that provides bioprocessing technologies and solutions for the manufacture of biological drugs. It operates throughout North America, Europe, the Asia-Pacific Region, and other geographic areas.